Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Miguel Serrano is active.

Publication


Featured researches published by Miguel Serrano.


BioDrugs | 2010

Autoimmune Hepatitis Induced by Infliximab in a Patient with Crohn’s Disease with no Relapse After Switching to Adalimumab

Marília Cravo; Rosa Silva; Miguel Serrano

Infliximab and adalimumab are anti-tumor necrosis factor (TNF) alpha agents used for treating Crohn’s disease. Autoimmune hepatitis (AIH) is a rare complication of treatment with these drugs. We report on a case of AIH in a patient with Crohn’s disease treated with infliximab who fully recovered after drug withdrawal. More interestingly, because there were no other treatment options, the patient was then treated with adalimumab without recurrence of the liver disease and with control of the intestinal disease.


Revista Espanola De Enfermedades Digestivas | 2013

Double-balloon enteroscopy in the management of patients with Peutz-Jeghers syndrome: A retrospective cohort multicenter study

Miguel Serrano; Susana Mão-de-Ferro; Rolando Pinho; Ricardo Marcos-Pinto; Pedro Figueiredo; Sara Ferreira; Isabel Claro; Miguel Mascarenhas-Saraiva; António Dias-Pereira

BACKGROUND AND OBJECTIVE Little is known about the clinical impact of double-balloon enteroscopy (DBE) in patients with Peutz- Jeghers syndrome (PJS).The aim of this study was to assess the efficacy and safety of DBE in the management of small-bowel polyps in PJS patients. PATIENTS AND METHODS We conducted a multicentre, retrospective cohort study, which included all consecutive patients diagnosed with PJS who underwent DBE for polypectomy between January 2006 and August 2012. In all cases, previous videocapsule enteroscopy had shown at least one polyp ≥ 10 mm in size. RESULTS Twenty-five patients (13 men; median age 36 years; 14 with prior laparotomy) underwent 46 DBE procedures (1 to 5 per patient, 44 via oral route). Polypectomy was performed in 39/46 DBEs. A total of 214 polyps were removed (median-size 30 mm), with a median number of polypectomies per procedure of 5.0 (range 1-18). The estimated maximum-sizes of resected polyps significantly decreased at each session: 30.0, 25.0, 20.0, 15.0, and 17.5 mm (p = 0.02). In 7 DBEs no polypectomy was performed (4-only minor polyps detected; 3-endoscopic irresecability). Complications occurred in 3/39 of therapeutic procedures (2-minor delayed bleeding; 1-mucosal tear), all of them dealt with conservative or endoscopic therapy. Six patients underwent elective surgery post DBE due to polyps not amenable for endoscopic resection. There were no small-bowel polyp related complications during a median follow-up of 56.5 months. CONCLUSION DBE showed to be a safe and effective technique in the management of small-bowel polyps in PJS patients, allowing a presymptomatic and non-surgical approach.


GE Portuguese Journal of Gastroenterology | 2017

Efficacy of Long-Term Oral Vitamin B12 Supplementation after Total Gastrectomy: Results from a Prospective Study.

Joana Moleiro; Susana Mão de Ferro; Sara Ferreira; Miguel Serrano; Margarida Silveira; António Dias Pereira

Background/Objectives: Vitamin B12 (VB12) deficiency is a common complication after total gastrectomy which may be associated with megaloblastic anemia and potentially irreversible neurologic symptoms. Intramuscular supplementation of VB12 has been considered the standard treatment, although it is associated with high costs and patient discomfort. Patients/Methods: We performed a prospective uncontrolled study (ACTRN12614000107628) in order to evaluate the clinical and laboratory efficacy of long-term oral VB12 supplementation in patients submitted to total gastrectomy. All patients received daily oral VB12 (1 mg/day) and were evaluated every 3 months (clinical and laboratory evaluation: hemoglobin, VB12, total iron, ferritin, and folate). Results: A total of 26 patients were included with a mean age of 64 years (29-79). Patients were included with a mean period of 65 months (3-309) after total gastrectomy. At inclusion time, 17/26 patients were under intramuscular VB12, and 9 had not started supplementation yet. There were normal serum VB12 levels in 25/26 patients (mean VB12 serum levels: 657 pg/mL). The mean follow-up period was 20 (8.5-28) months. During follow-up, all patients had normal VB12 levels and there was no need for intramuscular supplementation. The patient with low VB12 levels had an increase to adequate levels, which remained stable. There were no differences with statistical significance among VB12 levels at 6 (867 pg/mL), 12 (1,008 pg/mL), 18 (1,018 pg/mL), and 24 (1,061 pg/mL) months. Iron and folate supplementation was necessary in 21 and 7 patients, respectively. Conclusions: Oral VB12 supplementation is effective and safe in patients who underwent total gastrectomy and should be considered the preferential form of supplementation.


Clinical Endoscopy | 2018

Buried Barrett’s Esophagus with High-Grade Dysplasia after Radiofrequency Ablation

Joana Castela; Miguel Serrano; Susana Mão de Ferro; Daniela Pereira; Paula Chaves; António Dias Pereira

Radiofrequency ablation therapy is an effective endoscopic option for the eradication of Barrett’s esophagus that appears to reduce the risk of esophageal cancer. A concern associated with this technique is the development of subsquamous/buried intestinal metaplasia, whose clinical relevance and malignant potential have not yet been fully elucidated. Fewer than 20 cases of subsquamous neoplasia after the successful radiofrequency ablation of Barrett’s esophagus have been reported to date. Here, we describe a new case of subsquamous neoplasia (high-grade dysplasia) following radiofrequency ablation that was managed with endoscopic resection. Our experience suggests that a meticulous endoscopic inspection prior to and after radiofrequency ablation is fundamental to reduce the risk of buried neoplasia development.


Familial Cancer | 2012

Bethesda criteria for microsatellite instability testing: impact on the detection of new cases of Lynch syndrome

Miguel Serrano; Pedro Lage; Sara Belga; Bruno Filipe; Inês Francisco; Paula Rodrigues; Ricardo Fonseca; Paula Chaves; Isabel Claro; Cristina Albuquerque; António Dias Pereira


Acta Médica Portuguesa | 2012

Endoscopic Mucosal Resection of Superficial Colorectal Neoplasms: Review of 140 Procedures

Miguel Serrano; Susana Mão de Ferro; Paulo Fidalgo; Pedro Lage; Paula Chaves; António Dias Pereira


Dysphagia | 2016

Usefulness of Prophylactic Percutaneous Gastrostomy Placement in Patients with Head and Neck Cancer Treated with Chemoradiotherapy

Joana Moleiro; Sandra Faias; Catarina Fidalgo; Miguel Serrano; A. Dias Pereira


Revista Portuguesa de Cirurgia | 2016

Management of refractory anastomotic esophageal strictures with biodegradable stents

Joana Castela; S. Mão de Ferro; Miguel Serrano; Sheila Ferreira; Isadora Rosa; Pedro Lage; A. Dias Pereira


Jornal Português de Gastrenterologia | 2014

Caso invulgar de suboclusão intestinal: enteropatia por anti-inflamatórios não esteróides

Miguel Serrano; Susana Mão de Ferro; Sara Ferreira; Paula Chaves; António Dias Pereira


GE Jornal Português de Gastrenterologia | 2014

Endoscopic SpotAn uncommon case of partial small‐bowel obstruction: Non‐steroidal anti‐inflammatory drug enteropathyCaso invulgar de suboclusão intestinal: enteropatia por anti‐inflamatórios não esteróides

Endoscopic Spot; Miguel Serrano; Susana Mão de Ferro; Sara Ferreira; Paula Chaves; António Dias Pereira

Collaboration


Dive into the Miguel Serrano's collaboration.

Top Co-Authors

Avatar

António Dias Pereira

Instituto Português de Oncologia Francisco Gentil

View shared research outputs
Top Co-Authors

Avatar

Paula Chaves

Instituto Português de Oncologia Francisco Gentil

View shared research outputs
Top Co-Authors

Avatar

Susana Mão de Ferro

Instituto Português de Oncologia Francisco Gentil

View shared research outputs
Top Co-Authors

Avatar

Sara Ferreira

Instituto Português de Oncologia Francisco Gentil

View shared research outputs
Top Co-Authors

Avatar

Pedro Lage

Instituto Português de Oncologia Francisco Gentil

View shared research outputs
Top Co-Authors

Avatar

A. Dias Pereira

Instituto Português de Oncologia Francisco Gentil

View shared research outputs
Top Co-Authors

Avatar

Catarina Fidalgo

Instituto Português de Oncologia Francisco Gentil

View shared research outputs
Top Co-Authors

Avatar

Isabel Claro

Instituto Português de Oncologia Francisco Gentil

View shared research outputs
Top Co-Authors

Avatar

Joana Castela

Instituto Português de Oncologia Francisco Gentil

View shared research outputs
Top Co-Authors

Avatar

Joana Moleiro

Instituto Português de Oncologia Francisco Gentil

View shared research outputs
Researchain Logo
Decentralizing Knowledge